In this article
Novo Nordisk
on Monday said it is suing online telehealth provider Hims & Hers
for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in the U.S.
Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company’s patents, and is seeking to recover damages. In a release, Novo accused Hims of “deceiving patients and putting their health at risk,” as the safety, efficacy and quality of those copies are not verified by U.S. regulators.
